8-K current report · filed Aug 12, 2026

OMEROS CORP (OMER) 8-K Current Report: August 12, 2026

Item 2.02Item EX-99.1OMER overview

Short answer

OMEROS CORP (OMER) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Omeros reported financial results for the three and six months ended June 30, 2026.

OMEROS CORP 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Omeros reported financial results for the three and six months ended June 30, 2026
  • Detailed results and management commentary provided in Exhibit 99.1 press release
  • Information furnished under Item 2.02, not treated as filed under specified securities-law liability provisions

Item EX-99.1 · Exhibit EX-99.1

  • Q2 2026 YARTEMLEA gross revenue $32.2M, up 190% sequentially, with net revenue $28.5M
  • Adjusted net income $1.8M, or $0.02 per share, versus adjusted loss $17.1M in Q1, signaling initial commercial breakeven
  • Cash and short-term investments $132.0M, while operating cash flow turned positive at $4.1M for the quarter
  • 2029 Notes repurchase cost $60.2M, reducing principal to $40.3M, potential conversion shares to 6.5M, and future interest by $8.6M
  • EMA’s CHMP negative opinion on narsoplimab creates European approval risk despite a requested re-examination; U.S. commercialization remains the primary growth driver

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other OMEROS CORP 8-K filings

Get the next OMER 8-K as it lands

Follow OMER for push alerts, or ask the research agent what this filing means.